5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Deucravacitinib, a novel selective tyrosine kinase 2 inhibitor, may be a promising treatment option for patients with psoriatic arthritis, suggest phase 2 data presented in a poster at the ACR Convergence 2020 virtual meeting.

Five presentations at the ACR Convergence 2021 virtual meeting covered results from the phase 3b/4 postmarketing safety study, which was mandated by the US FDA and carried out between 2014 and 2020.

ACR Convergence 2021; 3–9 November (abstract L16) ACR Convergence 2021; 3–9 November (abstract L04)

ACR Convergence 2021; 3–9 November

ACR Convergence 2021; 3–9 November (abstract 1448) ACR Convergence 2021; 3–9 November (abstract 0815)

The study, which was reported at the ACR Convergence 2021 virtual meeting and published in The Lancet Rheumatology , included 1202 patients with one of these conditions who developed COVID-19 between March 2020 and April 2021.

ACR Convergence 2021; 3–9 November

Arthritis Care Res 2021; doi:10.1002/acr.24768

Related news story:  Upadacitinib shows promise for PsA SELECT-AXIS 1: Ankylosing spondylitis Phase 2/3 Patient population: Biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs Treatment groups: Upadacitinib 15 mg/day or placebo Status: Published https://clinicaltrials.gov/ct2/show/NCT03178487 The SELECT-AXIS 1 results were published in  The Lancet  and reported at the ACR/ARP Annual Meeting in Atlanta, Georgia, USA, in November 2019.

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

The JAK inhibitor tofacitinib is a promising treatment option for people with ankylosing spondylitis, suggest phase 3 trial findings presented at the ACR Convergence 2020 virtual meeting.

Patients with rheumatic diseases taking biologic therapy were more likely to shield during the first 6 months of the COVID-19 pandemic than those taking other drug types, shows research reported at the ACR Convergence 2020 virtual meeting.

Integration of clinical and protein biomarker data using a machine-learning approach may help to distinguish patients with psoriatic arthritis from those with psoriasis, suggests research presented at the ACR Convergence 2020 virtual meeting.

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

The autotaxin inhibitor ziritaxestat may improve skin fibrosis in patients with early diffuse cutaneous systemic sclerosis, show data from the phase 2a NOVESA study presented at the ACR Convergence 2020 virtual meeting.

COVID-19 is uncommon in children with rheumatic diseases and appears to result in mild illness when it occurs, suggest data presented at the ACR Convergence 2020 virtual meeting.

Research presented at the ACR Convergence 2020 virtual meeting provides reassurance that pregnant women with rheumatic diseases can expect a favorable outcome if they develop COVID-19.

Neihulizumab, a novel monoclonal antibody that binds to the cell-surface protein CD162, may reduce disease activity in patients with psoriatic arthritis, show phase 2a study data presented at the ACR Convergence 2020 virtual meeting.